Incyte | Le Bénéfice D'Exploitation



Operating Profit Changement Date
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Amgen USD 2.31B 182M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 3.41B 2.62B 2025-03
Eli Lilly USD 5.41B 259.6M 2025-03
Exelixis USD 163.21M 27.13M 2025-01
Gilead Sciences USD 2.24B 215M 2025-03
Incyte USD 205.17M 96.34M 2025-03
Ionis Pharmaceuticals USD -146000000 35.18M 2025-03
MacroGenics USD -16587000 70.78M 2024-12
Merck USD 5.87B 1.57B 2025-03
Moderna USD -1050000000 196M 2025-03
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Novartis USD 3.4B 193M 2024-12
Pfizer USD 3.67B 4.08B 2025-03
PTC Therapeutics USD -62489000 7.98M 2024-12
Regeneron Pharmaceuticals USD 591.7M 398.5M 2025-03
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Incyte Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.